Exchange: NASDAQ Global Select Sector: Healthcare Industry: Biotechnology
Current Signal: SELL (auto-tracking)
0.00% $2.21
/ 7 mai 2024 @ 09:37
FUNDAMENTALS | |
---|---|
MarketCap: | 334.80 mill |
EPS: | -0.830 |
P/E: | -2.66 |
Earnings Date: | May 09, 2024 |
SharesOutstanding: | 151.49 mill |
Avg Daily Volume: | 0.796 mill |
RATING 2024-05-06 |
---|
C+ |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Sell | |
Return On Asset: | Strong Sell | |
DE: | Neutral | |
P/E: | Sell | |
Price To Book: | Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -2.66 | sector: PE 0 |
PE RATIO: COMPANY / INDUSTRY |
---|
0x |
Company: PE -2.66 | industry: PE 0 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.248 (-88.79%) $-1.962 |
Date: 2024-05-07 |
Expected Trading Range (DAY) |
---|
$ 2.04 - 2.38 ( +/- 7.83%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-05 | Lim Jonathan E | Buy | 1 500 000 | Stock Option (right to buy) |
2024-02-05 | Chacko David M. | Buy | 600 000 | Stock Option (right to buy) |
2024-02-05 | Garner Ebun | Buy | 480 000 | Stock Option (right to buy) |
2024-02-05 | Morris Shannon | Buy | 535 800 | Stock Option (right to buy) |
2024-01-01 | Bristol James Arthur | Buy | 62 747 | Stock Option (right to buy) |
INSIDER POWER |
---|
91.39 |
Last 97 transactions |
Buy: 49 831 619 | Sell: 16 520 030 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $2.21 (0.00% ) |
Volume | 0.0139 mill |
Avg. Vol. | 0.796 mill |
% of Avg. Vol | 1.749 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:36 | buy | $1.745 | N/A | Active |
---|
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.